SOPHiA GENETICS technology to aid research associated with hereditary cancers and disorders
BOSTON and LAUSANNE, Switzerland – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Ankara Etlik City Hospital, the largest hospital in the capital city of Turkey, is live on the SOPHiA DDM™ Platform. The hospital, which opened its doors in September 2022 and serves roughly 15,000 patients daily, will utilize multiple SOPHiA GENETICS solutions to streamline genomic testing, specifically associated with hereditary disorders.
“Since opening our doors eight months ago, we’ve seen more than two million patients,” said Dr. Taha Bahsi, Head of Medical Genetics, Ankara Etlik City Hospital. “We are investing in technologies like SOPHiA DDM™ to best serve our community. The SOPHiA GENETICS technology will help create efficiencies in the analysis of genomic profiles and the identification of variants often associated with hereditary disorders such as cancers.“
Hereditary cancer is responsible for roughly one in 10 diagnosed cancers. Next-generation sequencing (NGS), is commonly used in the detection of biomarkers for hereditary cancers but produces a vast and complex data set that is timely for researchers to analyze. Using an array of sophisticated algorithms, the SOPHiA DDM™ Platform helps to streamline and expedite data analysis, which will save valuable time for clinical researchers. In addition, the tailored NGS-based workflows empower researchers to obtain high-quality, reproducible data that helps accelerate cancer research, including testing for new and existing therapies.
“The SOPHiA DDM™ Platform offers multiple applications paired with sophisticated algorithms that allow organizations such as Ankara Etlik City Hospital to increase the volume of research and testing,” said Abhimanyu Verma, Chief Technology Officer, SOPHiA GENETICS. “Our platform connects data points from institutions globally, allowing Ankara Etlik City Hospital’s researchers to expedite the analysis of genomic profiles and draw further insights that their teams can leverage to better care for the millions of people in and around the capital city of Ankara..”
Ankara Etlik City Hospital has implemented SOPHiA DDM™ applications that will create a streamlined workflow to help accelerate research and will enable Ankara Etlik City Hospital to develop an in-house database of genomic data and insights. This database will help to create efficiencies with research and support experts as they work to make data-driven decisions.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.